ea0029oc7.3 | Adrenal Clinical | ICEECE2012
Volante M.
, Terzolo M.
, Fassnacht M.
, Rapa I.
, Germano A.
, Sbiera S.
, Daffara F.
, Sperone P.
, Scagliotti G.
, Allolio B.
, Papotti M.
, Berruti A.
Purpose: Mitotane is the reference systemic therapy for adrenocortical carcinoma (ACC), but its mechanism of action and possible predictors of treatment response remain poorly defined. Our aim was to evaluate the gene expression of ribonucleotide reductase large subunit 1 (RRM1) and excision repair cross-complementation group 1 (ERCC1) in ACC as potential biomarkers for clinical outcome and response to mitotane.Experimental design: Forty-five and 47 tiss...